REG - GSK PLC - Director/PDMR Shareholding
21/02/2025 07:15
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250221:nRSU9189Xa&default-theme=true
RNS Number : 9189X GSK PLC 20 February 2025
GSK plc (the 'Company')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over Ordinary Shares
and American Depositary Shares ('ADSs') made to Persons Discharging Managerial
Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in
February 2022 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'),
which were subject to relevant business performance conditions, and the
subsequent sale of ordinary shares and ADSs to meet tax liabilities. Awards
were made in 2022 and the three-year performance period commenced on 1 January
2022 and ended on 31 December 2024. The vested shares for the Executive
Directors are now subject to an additional two-year vesting period.
The performance measure vesting details for those PDMRs who received awards in
2022 are set out in the following table.
Outcome and Vesting Level
Portion of the Award Measure and Outcome % of maximum % of award
30% Total Shareholder Return - For the three-year period the Company's Total 40% 12%
Shareholder Return ranked 5th, against a comparator group of 10 global
pharmaceutical companies including GSK.
20% Total Sales - For the three-year period, the Company achieved sales across our 100% 20%
marketed products for the measure of £86.15bn, which is above the level of
£80.29bn required for 100% vesting. The threshold vesting level was
£75.71bn.
20% Total Profit - For the three-year period, the Company achieved £24.2bn, which 100% 20%
is above the level of £23.62bn required for 100% vesting. The threshold
vesting level was £22.27bn.
20% Pipeline Progress - measure is equally weighted between:
- Pivotal trial starts 100% 10%
- Major regulatory approvals 87.5% 8.75%
10% Trust: Environment - For the three-year period, all criteria for achieving 100% 10%
our Trust priority and goal of having a Nature Net Positive and Climate Net
Zero impact by 2030 have been met or exceeded in advance of the target date
required to result in maximum vesting for this measure.
Total vesting for 2022 award 80.75 80.75%
Lapsed 19.25
The notifications that follow are for awards made to PDMRs and their PCAs and
detail the PSP conditional awards that vested, including dividends accrued, on
18 February 2025. The balance of the award made to each PDMR and PCA has
lapsed.
The closing prices of Ordinary Shares and of ADSs of GSK plc on the vesting
date were £14.43 and $36.61.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan. These shares are now subject to a
two-year hold.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 420,177
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 88,027
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 47,121
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 143,381
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 67,390
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 50,221
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 23,604
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 208,808
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 14,763
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction The number of ADSs vesting on awards granted in 2022 under the Company's 2017
Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 47,681
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction The sale of ADSs to meet tax liabilities for the vesting of awards granted in
2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$36.6355 25,705
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 153,657
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 72,219
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 135,261
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 63,573
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 70,869
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 33,309
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, GSK Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 133,405
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, GSK Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 62,701
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 97,444
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 45,799
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2022 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,755
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2022 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2531 5,055
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-18
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSEDFISEISEEERecent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Nucala MATINEE data in COPD published in NEJM
Announcement